Boehringer Ingelheim, MD Anderson launch virtual research and development center

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Shironosov)
(Image: Getty/Shironosov)

Related tags: Boehringer, Boehringer ingelheim, Research, development, Translational medicine, texas

Boehringer Ingelheim and the University of Texas MD Anderson Cancer Center entered a multi-year partnership to conduct collaborative translational research for lung and GI cancers.

The partnership sees the two organizations establishing a joint Virtual Research and Development Center to establish data sharing and analysis to advance research into gastrointestinal (GI) and lung cancer.

Tim Heffernan, executive director of the TRACTION platform at MD Anderson, told us, “By joining forces, this partnership enables access to multidisciplinary expertise that will accelerate the discovery and development of novel treatment options for patients with lung and GI cancers.”

The new center, while virtual in nature, will be responsible for advancing a portfolio of programs through preclinical and clinical development stages. The center will be funded by both Boehringer Ingelheim and MD Anderson and will include investigators from both organizations.

By working together, the two organizations can easily transfer data and access reagents and platforms as development progresses, said Heffernan.

The Virtual Research and Development Center also will focus on the development of potential new treatments including KRAS inhibition concepts, and a TRAILR2 agonistic antibody that has the potential to selectively induce cancer cell death.

“This partnership combines an innovative pipeline of KRAS and TRAIL-R2 targeting agents with unique research and translational platforms and a robust clinical infrastructure at MD Anderson,”​ said Heffernan.

MD Anderson’s Therapeutics Discovery division will be heavily involved in the collaborative work at the center. The division currently uses the organization’s Translational Research to Advance Therapeutics and Innovation in Oncology, or TRACTION, platform to establish translational research.

The team includes clinicians and researchers and uses the translational research platform to determine which patients will see the most benefit from the new medicines developed.

Heffernan said in a statement that the collaboration with Boehringer Ingelheim will enable MD Anderson to advance its innovative pipeline of cancer medicines. He added, “Our therapeutics discovery team is well-poised to conduct impactful translational research, and this partnership will allow us to more rapidly advance much-needed new therapies to patients.”

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more